Skip to main content

Our Companies

InVatin Technologies Ltd

InVatin Technologies Ltd. is developing the SYNAXIS-XT: The ultimate solution for stroke prevention in high risk patients.

The Need

Stroke develops when sections of the brain are deprived of oxygen. This is usually the result of embolic particles, or clots, blocking the blood vessels which supply these areas. Stroke is a devastating medical condition and a leading cause of permanent debilitation in adults. It is the second leading cause of death worldwide with an annual mortality of approximately 5.5 million.

Unfortunately, once stroke symptoms have progressed, therapeutic solutions are limited. Embolic stroke is commonly associated with cardiac rhythm disorders, such as atrial fibrillation. Although new drugs are presently available, the socioeconomic and financial burden of people suffering from strokes has not been significantly reduced. Importantly, the same drugs that are used to prevent strokes substantially increase the risk of life-threatening bleeding and, paradoxically, may cause hemorrhagic stroke.


Development Stage
Preclinical studies

InVatin’s Solution

InVatin Technologies Ltd, developed the SYNAXIS- XT, an aortic arch, uni-axial, diverter designed to deliver embolic protection to all three arteries ascending from the aortic arch, minimizing the risk for cerebral ischemic stroke. The device contains a unique mechanical barrier which redirects emboli away from the brain while preserving blood flow patterns and maintaining uncompromised stent patency. This novel technology marks a paradigm shift in stroke prevention for high risk patients; A paradigm in which patients can be protected from stroke regardless of the origin of the embolic substance, or underlying condition.

Dr. Udi Nussinovitch MD PhD, Founder, CSO and Chairman of the Board

Experienced cardiology fellow, skilled in medical devices development and cardiovascular research. Director of the Applicative Cardiovascular Research Center (ACRC), Meir Medical Center, Israel.

Dr. Elon Reshef, DVM,

20 years of experience in R&D, clinical and business development from medical device companies such as Eqlibra Medical, Allium Medical, MindGuard, Biosense-Webster, BiolineRX and many more.

The Market Opportunity

Stroke related costs are currently estimated at $72B per year. These costs are expected to grow significantly in years to come, with an estimated $94.3B in spending by 2035. As the population ages and life expectancy increases, strokes are poised to become one of the most expensive problems in healthcare.

Atrial Fibrillation (AF) affects more than 9% of the adult population aged 65 or older. Patients are treated primarily with anti-coagulation drugs ($11.5B/Year in spending, 2018). Approximately 20% of these patients develop bleeding or side effects which prevent them from continuing treatment. Non-AF patients who are at risk for stroke are also treated with anti-coagulation drugs ($4.5B/Year in spending, 2018), and we estimate that 35% of these patients are prime candidates for our product. Thus, we can expect a direct market of $2.3B from AF patients, and nearly $1.6B from non-AF patients. In total, we estimate a $3.9B per year market for the SYNAXIS-XT.

Skip to content